{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:06:37Z","timestamp":1788397597600,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006437","name":"CeNeRx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006437","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bracket Global (Wayne, PA)"},{"DOI":"10.13039\/100014387","name":"Acadia Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alkermes Inc."},{"DOI":"10.13039\/100015491","name":"BrainCells Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Forum Pharmaceuticals"},{"name":"Functional Neuromodulation Inc."},{"name":"Intracellular Therapies, Inc."},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson PRD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Methylation Sciences Inc."},{"name":"Navitor"},{"name":"Neurim Pharmaceuticals"},{"name":"Prana Biotechnology Ltd."},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Resilience Therapeutics"},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalofpsychiatricresearch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jpsychires.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T00:46:02Z","timestamp":1504917962000},"page":"276-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Early symptomatic improvement affects treatment outcome in a study of major depressive disorder"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-5197","authenticated-orcid":false,"given":"Steven D.","family":"Targum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2017.09.009_bib1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4236\/ojd.2014.33015","article-title":"Does early improvement in anxiety symptoms in patients with major depressive disorder affect remission rates? a post-hoc analysis of pooled duloxetine clinic trials","volume":"3","author":"Altin","year":"2014","journal-title":"Open J. Depress."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/BF00978365","article-title":"Monoamine oxidase inhibitors and the cheese effect","volume":"18","author":"Anderson","year":"1993","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib4","series-title":"Moderating Factors Affect Signal Detection with MSI-195 Vs. Placebo in a Major Depressive Disorder Augmentation Trial","first-page":"2016","author":"Cameron","year":"2016"},{"issue":"5","key":"10.1016\/j.jpsychires.2017.09.009_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","article-title":"Validation of the Massachusetts general hospital antidepressant treatment history questionnaire (ATRQ)","volume":"16","author":"Chandler","year":"2010","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.jpsychires.2017.09.009_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4088\/JCP.v68n0107","article-title":"Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications","volume":"68","author":"Cusin","year":"2007","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004714-200112000-00004","article-title":"The double blind variable placebo lead-in period: results from two antidepressant clinical trials","volume":"6","author":"Faries","year":"2001","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2017.09.009_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A\u00a0rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiat."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib10","first-page":"94","article-title":"Early symptom change: prediction of remission in depression treatment","volume":"42","author":"Katz","year":"2009","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.jpsychires.2017.09.009_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-0327(89)90021-9","article-title":"Onset of response in relation to outcome in depressed outpatients with placebo and imipramine","volume":"17","author":"Khan","year":"1989","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.NMD.0000061144.16176.38","article-title":"Placebo response and antidepressant clinical trial outcome","volume":"191","author":"Khan","year":"2003","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/wps.20421","article-title":"Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US food and drug administration 1987-2013","volume":"16","author":"Khan","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib14","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.jpsychires.2017.09.009_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0b013e31802eb4b7","article-title":"Why do clinical trials Fail?: the problem of measurement error in clinical trials: time to test new paradigms?","volume":"27","author":"Kobak","year":"2007","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib16","series-title":"Handbook of Psychotherapy Integration","first-page":"94","author":"Lambert","year":"1992"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archpsyc.1995.03950220077014","article-title":"More reliable outcome measures can reduce sample size requirements","volume":"52","author":"Leon","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1353\/pbm.0.0115","article-title":"The placebo effect: illness and interpersonal healing","volume":"52","author":"Miller","year":"2009","journal-title":"Perspect. Biol. Med."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A\u00a0new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/sj.npp.1300405","article-title":"Placebo-controlled continuation treatment with mirtazapine: acute patterns of resonse predict relapse","volume":"29","author":"Nierenberg","year":"2004","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0006-3223(00)00837-4","article-title":"Penny wise and dollar foolish: the impact of measurement error on sample size requirements in clinical trials","volume":"47","author":"Perkins","year":"2000","journal-title":"Biol. Psychiat."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/ajp.148.2.193","article-title":"Heterogeneity of clinical response during placebo treatment","volume":"148","author":"Quitkin","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1755-5949.2008.00038.x","article-title":"Re-defining affective disorders: relevance for drug development","volume":"14","author":"Targum","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.euroneuro.2014.06.003","article-title":"Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients","volume":"24","author":"Targum","year":"2014","journal-title":"Eur. J. Neuropsychopharmocol."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib25","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.euroneuro.2014.08.016","article-title":"Audio-digital recordings used for independent confirmation of site-rated MADRS interview scores","volume":"24","author":"Targum","year":"2014","journal-title":"Eur. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib26","unstructured":"Targum, S.D., Catania, C.J. Signal Detection Is Affected by Early Symptomatic Improvement in a Double-blind, Placebo-controlled Depression Study. (Submitted for publication)."},{"key":"10.1016\/j.jpsychires.2017.09.009_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1192\/bjp.bp.111.093336","article-title":"Assessing the \u2018true\u2019 effect of active antidepressant therapy v. placebo in major depressive disorder","volume":"199","author":"Thase","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/npp.1994.63","article-title":"Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?","volume":"11","author":"Trivedi","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpsychires.2016.03.001","article-title":"Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design","volume":"78","author":"Trivedi","year":"2016","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"14","key":"10.1016\/j.jpsychires.2017.09.009_bib30","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2017.09.009_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the montgomery\u2013\u00e5sberg depression rating scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Brit. J. Psychiat."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239561730599X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239561730599X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:08:15Z","timestamp":1750871295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002239561730599X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":33,"alternative-id":["S002239561730599X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.09.009","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early symptomatic improvement affects treatment outcome in a study of major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}